"The US Food and Drug Administration (FDA) has approved an expanded indication for onabotulinum toxin A (Botox, Actavis) for the treatment of adults with upper limb spasticity, according to a company news release.
The expanded i"...
Nimbex Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Nimbex (cisatracurium besylate) is a skeletal muscle relaxant given before general anesthesia in preparation for surgery. It helps keep the body still during surgery. Nimbex also relaxes the throat so a breathing tube can be more easily inserted before surgery. Nimbex is available in generic form. Common side effects of Nimbex include light-headedness, mild itching or skin rash, warmth, redness, or tingly feeling under the skin.
Doasge of Nimbex is individualized based on the patient's condition, weight and other factors. Nimbex may interact with lithium, seizure medications, heart rhythm medications, tetracycline antibiotics, or an aminoglycoside. Tell your doctor all medications you use. Tell your doctor if you are pregnant or plan to become pregnant during treatment with Nimbex. It is unknown if this medication passes into breast milk or if it could harm a nursing baby. Consult your doctor before breast-feeding.
Our Nimbex (cisatracurium besylate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Nimbex in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:
- slow heart rate;
- noisy breathing, feeling short of breath;
- ongoing muscle weakness; or
- inability to move your muscles.
Less serious side effects may include:
- feeling light-headed;
- mild itching or skin rash; or
- warmth, redness, or tingly feeling under your skin.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Nimbex (Cisatracurium Besylate)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Nimbex FDA Prescribing Information: Side Effects
Observed in Clinical Trials of Surgical Patients
Adverse experiences were uncommon among the 945 surgical patients who received NIMBEX (cisatracurium besylate) in conjunction with other drugs in US and European clinical studies in the course of a wide variety of procedures in patients receiving opioid, propofol, or inhalation anesthesia. The following adverse experiences were judged by investigators during the clinical trials to have a possible causal relationship to administration of NIMBEX (cisatracurium besylate) :
Incidence Greater than 1%
Incidence Less than 1%
Observed in Clinical Trials of Intensive Care Unit Patients
Adverse experiences were uncommon among the 68 ICU patients who received NIMBEX (cisatracurium besylate) in conjunction with other drugs in US and European clinical studies. One patient experienced bronchospasm. In one of the two ICU studies, a randomized and double-blind study of ICU patients using TOF neuromuscular monitoring, there were two reports of prolonged recovery (167 and 270 minutes) among 28 patients administered NIMBEX (cisatracurium besylate) and 13 reports of prolonged recovery (range: 90 minutes to 33 hours) among 30 patients administered vecuronium.
Observed During Clinical Practice
In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of cisatracurium besylate in conjunction with one or more anesthetic agents in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to cisatracurium besylate.
Histamine release, hypersensitivity reactions including anaphylactic or anaphylactoid reactions which in some cases have been life threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS and PRECAUTIONS). There are rare reports of wheezing, laryngospasm, bronchospasm, rash and itching following administration of NIMBEX (cisatracurium besylate) in children. These reported adverse events were not serious and their etiology could not be established with certainty.
Prolonged neuromuscular block, inadequate neuromuscular block, muscle weakness, and myopathy.
Read the entire FDA prescribing information for Nimbex (Cisatracurium Besylate)
Additional Nimbex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.